bioAffinity Technologies advances CyPath Lung for post-treatment surveillance
bioAffinity Technologies said it is advancing CyPath Lung as a noninvasive surveillance option for lung cancer patients after curative-intent treatment.
bioAffinity Technologies is advancing its CyPath® Lung test as a noninvasive option for surveillance of lung cancer patients after curative-intent treatment.Key Highlights:Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 8-K - Sep.
01, 2026This is an AI-powered summary.
It may contain…